No Data
Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday
HUTCHMED Appoints Experienced Director to Board
hutchmed (china) (00013.HK) appointed Hu Chaohong as an independent non-executive director and a member of the technical committee.
On November 20, Hutchmed (China) (00013.HK) announced today that Dr. Hu Chaohong has been appointed as an independent non-executive director and member of the Technology Committee of the company, effective from November 21, 2024. Dr. Hu has over 20 years of experience in therapeutic antibodies, antibody-drug conjugates, and vaccine development. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading multiple research and development programs. Dr. Hu's expertise spans from early discovery to clinical development and commercialization. She also has a successful track record in business development and establishing strategic partnerships (including licensing and collaborations) successfully.
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Express News | Hong Kong pharmaceutical stocks strengthened, with Innovent Bio rising more than 4%.
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
No Data
No Data